Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)

• Status: Completed
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy and safety of chloroquine prophylaxis on the incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections in healthcare workers exposed to patients with confirmed Coronavirus Disease 2019 (COVID-19)

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Fundacion Clinica Valle del Lili
• Treatments: Chloroquine

Criteria

Inclusion Criteria:

• Asymptomatic healthcare workers and contractors who work in Fundacion Valle del Lili

Exclusion Criteria:

• To have two or more of the following symptoms 14 days previous to the initial assessment: cough, dyspnea, odynophagia, fatigue, weakness, fever >38 degrees °C

• History of close contact (less than two meters) with a person with probable or confirmed COVID-19 without adequate protection during the last 14 days

• History of one the following diseases in treatment at inclusion in the study: cardiac arrhythmias, epilepsy, kidney disease, seizures

• Treatment with concomitant medications: tamoxifen, quinine, cyclosporine, amiodarone, digoxine, anticonvulsivants

• Having recently taken chloroquine or hydroxychloroquine in the last two weeks

• Known hypersensitivity to chloroquine or hydroxychloroquine